Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Files Lasofoxifene NDA For Treatment Of Osteoporsis

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Pfizer could be just one step behind Wyeth in getting a new selective estrogen receptor modulator approved and on the market for the treatment of osteoporosis in postmenopausal women. The drug maker has submitted an NDA for Fablyn (lasofoxifene, formerly Oporia) in that indication, development partner Ligand announced Jan. 15.

Related Content

Pfizer/Ligand Lasofoxifene Is First "Next-Generation" SERM Filed At FDA





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts